Search Bar & Filters
Found 43 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying 89Zr-TLX250, a diagnostic imaging agent, to detect clear cell renal cell carcinoma ccRCC in Chinese patients with indeterminate renal masses. This Phase 3, open-label, single-arm study aims to confirm the safety, tolerability, sensitivity, and specificity of 89Zr-TLX250 PETCT imaging. The study supports prior ZIRCON trial data and involves adult patients scheduled for partial or total nephrectomy as part of their standard care. Participants will receive a single intravenous dose of 37 MBq of 89Zr-TLX250 containing 10 mg of girentuximab. Imaging of the abdomen using PETCT will be performed 5 days post-administration, with possible whole-body imaging if widespread disease is suspected. Nephrectomy will occur any time after imaging but within 90 days. Histological analysis of tumor samples will confirm diagnosis. The study includes approximately seven visits over 4 to 6 months. Assessments include baseline exams, PETCT imaging, surgery, and follow-up visits. Imaging and histological data will be centrally analyzed to evaluate diagnostic accuracy. Safety and tolerability will be monitored throughout. The study is expected to last about 12 months with 4 months of follow-up per participant.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, immune response, and early clinical effects of BNT3212, both alone and combined with pumitamig, in adults with advanced solid tumors who have exhausted other treatment options. This first-in-human, open-label study includes dose escalation and expansion phases to find the best dose and assess how the treatments work across different tumor types. The study is divided into four parts Part A and Part B focus on BNT3212 as a single therapy, with dose escalation followed by dose expansion in specific tumor types. Parts C and D evaluate the combination of BNT3212 with a fixed dose of pumitamig, again starting with dose escalation and then expansion cohorts. Treatments are given by intravenous infusion, and doses are adjusted to find the maximum tolerated dose and recommended dose for further study. Participants will undergo regular monitoring including safety assessments, blood tests to study drug levels and immune reactions, and imaging to measure tumor response. Researchers will track side effects, treatment interruptions, and response rates over approximately 31 months. The study also measures progression-free and overall survival. Continuous evaluation of safety and clinical data supports participant well-being throughout the trial.
Actively Recruiting
Researchers are studying RC288, a drug being evaluated for its safety, tolerability, and effectiveness in treating locally advanced unresectable or metastatic malignant solid tumors. The study aims to find the highest safe dose and the recommended dose for further testing while assessing how well the drug works at that dose. This is a Phase III clinical trial sponsored by RemeGen Co., Ltd., involving multiple centers. Participants receive RC288 through intravenous infusion. The study includes six predefined dose levels that increase stepwise in Phase I to determine the maximum tolerated or administered dose. In Phase II, the recommended dose is further tested across various cancer types to evaluate safety and effectiveness. Patients continue treatment until they experience unacceptable side effects, disease progression, or meet criteria for withdrawal. During the study, participants undergo regular assessments including imaging to measure tumor responses, evaluations for adverse events, and monitoring of vital organ functions. Researchers will collect data over 24 months on dose-limiting toxicities, side effect severity, and tumor response rates using established criteria. The trial lasts up to approximately four years with ongoing safety monitoring and efficacy assessments throughout.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of two different approaches to bronchoscopic thermal vapor ablation BTVA treatment using the InterVapor System in patients with severe emphysema. The study compares treating at least two subsegments in different lung segments versus treating at least one whole lung segment. This multi-center randomized controlled trial aims to provide precise treatment options for patients with severe emphysema while continuing optimal medical therapy. Participants are randomly assigned to one of two groups the experimental group receives BTVA treatment targeting at least two subsegments of different lung segments in a single procedure, while the control group receives treatment targeting at least one whole segment per procedure. Each patient undergoes a sequential treatment with a minimum of 6 weeks and up to 6 months between procedures, with a maximum treatment volume defined per procedure and cumulatively across two treatments. Alongside BTVA, all participants continue receiving medical therapy following GOLD guidelines throughout the study. During the study, patients will have follow-up visits at 1, 3, 6, and 12 months after the second procedure. These visits include tests to assess lung function, high-resolution CT scans, a 6-minute walk test, and questionnaires measuring quality of life and respiratory symptoms. The main outcome being evaluated is lung function improvement measured by FEV1 six months after the second procedure. Secondary outcomes include lung volume changes, other lung function measures, exercise capacity, symptom assessments, responder rates, and recording of any adverse events during and up to one year after treatment.
Actively Recruiting
Researchers are conducting a multicenter, non-interventional, descriptive study to collect and analyze tumor samples from patients with various solid tumors, including non-small cell lung cancer NSCLC, gynecological cancers, biliary tract cancer BTC, and urothelial carcinoma UC. The study aims to assess the agreement between different laboratory tests for HER2 protein expression using immunohistochemistry IHC in Chinese pan-tumor patients. This research includes about 2100 patients diagnosed between January 2023 and September 2025 across 12 sites. The study has two phases enrollment and assessment. During enrollment, retrospective collection of tumor samples occurs, and HER2 status is tested locally using the Roche 4B5 assay. A committee reviews these results. In the assessment phase, 320 patients are selected to represent different HER2 expression levels across the tumor types. Tissue samples are sectioned and tested by multiple assays at central laboratories, and digital images of some slides are interpreted by 36 trained pathologists to evaluate consistency between tests and interpretations. Participants contribute by providing archived tumor tissue samples with sufficient slides for HER2 testing. The study evaluates the agreement between different HER2 testing assays and the consistency among pathologists interpreting these results. Researchers measure various concordance outcomes over approximately six months, including positive and negative percent agreements and inter-observer agreement. The study does not involve any treatment, and participant involvement mainly consists of sample provision and data collection from existing records.
Actively Recruiting
Researchers are evaluating treatments for women with hormone receptor-positive, HER2-negative advanced breast cancer that has returned or progressed after endocrine therapy. This phase II clinical trial studies the effects of entinostat combined with fulvestrant, with or without the addition of anlotinib, in patients who have previously been treated with CDK46 inhibitors. The study aims to understand how these treatments affect tumor response and disease progression. Participants receive entinostat tablets once a week and fulvestrant injections on specific days within a 28-day cycle. One group receives just entinostat and fulvestrant, while another group receives those plus anlotinib capsules taken daily for two weeks followed by a one-week break, forming a 3-week treatment cycle. Treatment continues until disease progression, intolerable side effects, withdrawal, or other protocol-defined conditions occur. Throughout the study, tumor response is evaluated every 8 weeks using RECIST criteria. Safety is continuously monitored during treatment, with follow-up visits shortly after treatment ends. The study concludes when disease progression occurs or when treatment stops for any reason. Participants are assessed up to two years for response rate, progression-free survival, clinical benefit, and duration of response.
Actively Recruiting
Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.
Actively Recruiting
Researchers are studying whether fecal microbiota transplantation FMT can help treat gastrointestinal symptoms caused by chemotherapy or targeted therapy in patients with gastrointestinal cancers. This Phase 1 trial aims to evaluate the effect of FMT on the gastrointestinal tract in these patients, focusing on those with advanced gastrointestinal tumors. The goal is to understand how FMT might reduce side effects linked to cancer treatment. Participants are randomly assigned to one of two groups. The control group continues their usual chemotherapy or targeted therapy cycles every three weeks for five cycles, with treatment effectiveness assessed after every two cycles. The experimental group receives FMT starting from the fourth treatment cycle, with capsules containing donor gut bacteria given orally within three days before chemotherapy during the fourth, sixth, and eighth cycles. Each FMT dose includes about 40 grams of bacteria encapsulated into 120 capsules, taken over a short period during each treatment cycle. Throughout the study, patients undergo regular assessments to track gastrointestinal symptoms and gut microbiota changes. Researchers monitor the incidence and improvement of gastrointestinal side effects at 4 and 8 weeks after FMT. They also analyze gut microbiota diversity and its correlation with symptom improvement. Participants are followed during treatment cycles and for a post-treatment period to evaluate these outcomes, with safety and organ function closely observed.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of JMT203 in patients with cancer cachexia, a condition characterized by severe weight loss in people with cancer. This study includes two parts Phase Ia, focusing on dose escalation and expansion to find safe and effective doses, and Phase II, a randomized, double-blind, placebo-controlled trial involving patients with colorectal cancer cachexia, pancreatic cancer cachexia, or cachexia from other solid tumors. The study aims to determine the recommended dose for future studies and assess preliminary treatment effects over 12 weeks. During Phase Ia, JMT203 will be tested in increasing doses using an accelerated titration design with a 33 dose escalation scheme. Dose expansion will select 1 to 3 potentially effective doses based on safety and pharmacokinetic data. In Phase II, participants will be randomly assigned to receive either JMT203 at 50 mg or 150 mg, or a placebo, administered as subcutaneous injections every three weeks for 12 weeks. An open-label extension phase may continue treatment at 150 mg or the recommended Phase 3 dose for up to 51 weeks. Participants will undergo regular assessments including monitoring adverse events, dose-limiting toxicities, and changes in body weight and muscle mass. Imaging by computed tomography and questionnaires about anorexia severity will be used to evaluate effects. Pharmacokinetic measurements and antibody responses will be tracked up to 90 days after dosing. The study also monitors survival and progression-free survival up to three years. Participants can expect visits for treatment administration, safety checks, and evaluation of their cancer cachexia symptoms throughout the study period.
1-10 of 43
1